Skip to content
News Product launch

Anthropic launches Claude Science, a research workbench with 60+ scientific database connections, in beta for paid subscribers

· by Pondero Newsdesk

The short version

Anthropic launched Claude Science on June 30, a purpose-built research environment for scientists that integrates more than 60 curated databases, manages cluster compute, and ships an internal drug-discovery program targeting neglected diseases.

Anthropic launches Claude Science, a research workbench with 60+ scientific database connections, in beta for paid subscribers

Anthropic raised Claude Science to flagship product status on June 30, putting it alongside Claude Code and Claude Cowork as one of three named product lines the company now actively develops. The tool shipped in beta to all paid Claude subscribers the same day, with no additional fee announced.

What

Built as a standalone app for macOS and Linux, Claude Science connects to more than 60 curated scientific databases and manages computing jobs on a researcher's existing infrastructure or on-demand GPU resources per Anthropic's announcement. UniProt, PDB, Ensembl, Reactome, ClinVar, and ChEMBL are among the databases in scope, all queryable in plain language through specialist sub-agents without the researcher writing bespoke data pipelines for each.

A coordinating agent delegates tasks to specialist sub-agents covering genomics, single-cell analysis, proteomics, structural biology, and cheminformatics. A separate reviewer agent checks citations and calculations as work runs, flagging untraceable numbers and figures that don't match the code that generated them. Every output carries an auditable history that traces each result back to its source data and code, making results reproducible months after the fact per Anthropic.

On compute, Claude Science submits jobs to the researcher's HPC cluster over SSH or scales to hundreds of GPUs via Modal. Large datasets stay on the lab's own infrastructure; only the context needed for each analysis step is sent to Claude.

Alongside the product launch, Anthropic said it is starting an internal drug discovery program aimed at neglected diseases that traditional pharmaceutical companies do not pursue. Using Claude Science directly, the company plans to run drug-candidate research to improve the product and pursue humanitarian goals.

Credit grants of up to $30,000 each will go to 50 selected external AI-for-science projects. Applications close July 15, 2026; projects run September 1 through December 1. Modal is providing up to $2,000 in additional compute credits for select grant recipients.

Why it matters

Scientists who already use Claude Code for analysis pipelines get a focused environment where the tool knows the databases, file formats, and compute patterns specific to life sciences without custom configuration on every project. Reproducibility is the concrete differentiator from a general coding assistant: figures include the exact code and environment that generated them, so a collaborator or peer reviewer can recheck the output rather than trust it.

Anthropic's internal drug discovery program signals the company is betting on Claude Science for real-world research, not only selling access to it. Running real drug-candidate pipelines internally means the product faces genuine scientific workloads as a forcing function, not just polished demos. Teams evaluating whether to build around Claude Science will find that a more credible accountability signal than a vendor roadmap.

Publicly traded AI drug discovery stocks fell on the launch date per CNBC, reflecting investor concern that Anthropic is entering territory those companies currently occupy.

Claude Science is available now at claude.com/science for Pro, Max, Team, and Enterprise subscribers. Team and Enterprise accounts require admin enablement first.

Context

Anthropic described Claude Science as a successor to the "Claude for Life Sciences" plug-ins it released last October, which connected Claude to scientific software and databases but did not constitute a standalone product. Elevating the product to the same tier as Claude Code reflects a strategic bet that scientific applications can become a major revenue line ahead of the company's IPO, as MIT Technology Review noted per MIT Technology Review.

The launch also closely follows Anthropic hiring John Jumper, the Nobel Prize-winning researcher who co-developed AlphaFold at Google DeepMind. Jumper's move to Anthropic and the simultaneous launch of a product oriented around protein structure analysis and drug discovery were not coincidental in timing.

What to watch next

The 50 external grant projects will run through December 2026, producing a first set of public results by early 2027. Watch for Anthropic to disclose which of those projects publish findings or report production use. The pricing question for Claude Science has not been resolved publicly; the current beta-with-no-added-cost arrangement is explicitly a feedback-gathering phase, and an Enterprise pricing tier seems likely before general availability.

Sources